Jiangxi Rimag Group’s Strategic 18% Stake Acquisition

Jiangxi Rimag Group Co., Ltd. Class H (HK:2522) has released an update.

Jiangxi Rimag Group Co., Ltd. has announced a significant acquisition with its subsidiary, Rimag Health Management, agreeing to purchase an 18% equity interest in the Target Company for RMB17.28 million. This transaction, involving key figures like Mr. CHEN Zhaoyang, is classified as a connected transaction, highlighting the interconnected nature of the involved parties. Although still subject to conditions, this deal underscores Rimag’s strategic expansion efforts.

For further insights into HK:2522 stock, check out TipRanks’ Stock Analysis page.